EcoR1 Capital’s Aligos Therapeutics ALGS Stock Holding History

EcoR1 Capital’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-88,569	Closed	-$731K	–	38
2025 Q1	$731K	Sell	88,569 -167,004	-65%	-$3.66M	0.04%	44
2024 Q4	$10.2M	Hold	255,573	–	–	0.38%	40
2024 Q3	$2.21M	Sell	255,573 -6	-0%	-$75	0.08%	55
2024 Q2	$2.24M	Hold	255,579	–	–	0.07%	53
2024 Q1	$6.26M	Hold	255,579	–	–	0.16%	50
2023 Q4	$4.24M	Buy	255,579 +97,645	+62%	+$1.68M	0.11%	39
2023 Q3	$2.95M	Hold	157,934	–	–	0.1%	42
2023 Q2	$3.83M	Hold	157,934	–	–	0.09%	43
2023 Q1	$3.45M	Hold	157,934	–	–	0.11%	41
2022 Q4	$3.76M	Hold	157,934	–	–	0.11%	51
2022 Q3	$4.34M	Hold	157,934	–	–	0.13%	52
2022 Q2	$4.78M	Hold	157,934	–	–	0.16%	48
2022 Q1	$8.49M	Buy	157,934 +154,292	+4,236%	+$12.4M	0.27%	44
2021 Q4	$1.08M	Buy	+3,642	New	+$1.33M	0.03%	64

Other funds holding ALGS

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RAM

Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

EcoR1 Capital's ALGS Position: Q2 2025 in Review

EcoR1 Capital sold out of Aligos Therapeutics (ALGS) in Q2 2025, closing a stake of 88,569 shares — an estimated $731K sold.

EcoR1 Capital first reported a position in ALGS in Q4 2021 and held it in 14 quarters. The position peaked at $10.2M in Q4 2024. 37 funds tracked by Wall St. Rank hold ALGS as of Q2 2025.

EcoR1 Capital reported no remaining Aligos Therapeutics position as of Q2 2025 after selling out during the quarter.
EcoR1 Capital sold 88,569 Aligos Therapeutics shares in Q2 2025, an estimated $731K.
EcoR1 Capital first reported a position in Aligos Therapeutics in Q4 2021 and held it in 14 quarters.
EcoR1 Capital's Aligos Therapeutics position peaked at $10.2M in Q4 2024.
37 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2025.

Based on EcoR1 Capital's 13F filing for Q2 2025, filed 14 Aug 2025.